AnHeart Therapeutics and Foundation Medicine Inc. have entered a strategic collaboration for the development and regulatory approval of Foundation Medicine’s tissue- and liquid-based comprehensive genomic profiling tests, FoundationOne CDx and FoundationOne Liquid CDx, as companion diagnostics for AnHeart’s investigational next-generation ROS1 inhibitor, taletrectinib, in the United States.
Fuse Oncology and the University of Michigan formed a strategic collaboration focused on radiation oncology.Â
It’s a divorce everyone has an opinion on.
NIH and FDA envision transforming the way clinical trials are done across the biomedical research enterprise.Â
From the time of its inception, the Worldwide Innovative Network (WIN) Consortium in precision cancer medicine has had a bold mission to significantly improve survival of patients with cancer across the world through international collaboration.
As 2024 approaches, it’s anyone’s guess whether an already complex health care ecosystem gets to turn the corner on the mixed legacies of 2023—including record high prices on new blockbuster medications coupled with drug shortages on existing generics, persistent staff shortages and battered hospital margins, and a continued emphasis on value-based care programs by insurers.Â
To the editor, I was not booed off the stage. Rather, the response was incredibly enthusiastic. After my session people lined up for over 45 minutes to talk to me. Many thanked me for publicizing this issue, indicating that the problems with the Illumina platform have been apparent to many, but no one else was... […]
Walter J. Curran Jr., former executive director of Winship Cancer Institute of Emory University, was named chief of Piedmont Oncology Institute (Piedmont Oncology), effective Jan. 9.
Angela J. Yoon was named director of the MUSC Hollings Cancer Center Biorepository and Tissue Analysis Shared Resource, effective Dec. 1; she will oversee a growing collection of cancer-associated biospecimens that allow researchers to translate Biological discoveries into prevention, diagnosis and treatment of cancer.
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center have received two grants totaling $9.1 million from NCI to advance liquid biopsy technologies for the early detection of cancer, which can significantly improve treatment outcomes and reduce the number of deaths caused by the disease.
